Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
 shares announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 30, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New Jersey on behalf of certain purchasers of shares of Agile Therapeutics Inc (NASDAQ:AGRX) over alleged Securities Laws Violations by Agile Therapeutics Inc.
Investors who purchased shares of Agile Therapeutics Inc. (NASDAQ:AGRX) have certain options and for certain investors there are short and strict deadlines running. Deadline: March 7, 2017. NASDAQ: AGRX investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants allegedly failed to disclose that the Twirla contraceptive patch had an efficacy rating that fell below peer group standards, that over half of patients in its “Secure” Phase 3 Study discontinued the study early, that the Twirla patch therefore allegedly had a slight chance of FDA approval, and that, as a result of the foregoing, Defendants’ statements about Agile Therapeutics’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On January 3, 2017, Agile Therapeutics Inc. announced results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile's initial marketing application back in 2013. The Company cited "positive top-line results" in the study, yet reported that almost 2% of subjects experienced "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression."
Those who purchased Agile Therapeutics Inc (NASDAQ:AGRX) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
